Almac is pleased to announce the doubling of analytical capacity at its 240,000 sq. ft. North American Headquarters. The facility - built on a 40 acre site in Souderton, north of Philadelphia (PA) - and occupied since 2010, delivers full-service, integrated clinical packaging, drug supply management and technology solutions to pharmaceutical and biotech clients. The site boasts state of the art analytical labs, supplementing existing facilities in the UK.

The analytical labs provide support for clinical packaging operations as well as stand-alone analytical services and are equipped with the latest equipment, including HPLC, UPLC, GC, UV, IR, DSC, KF and others. The additional lab investment will continue to offer these services in addition to polymorph and salt screening and solid form development.

In continuing its investment, the new lab will also be equipped with the latest bathless dissolution apparatus for rapid and efficient comparative dissolution studies. This provides maximum flexibility for developing, validating and running assays, dissolution and stability methods, further complementing the large capacity stability chambers which provide all the required ICH stability conditions.

Dr. Aeri Park, Operations Director commented: ‘”We always anticipated growth within our facility and are delighted that it has become necessary so quickly.This is testament to the dedication and commitment of our analytical team and we very much look forward to continued growth, coupled with superlative customer service in supporting clinical packaging operations and our stand-alone analytical and solid form businesses.”

The analytical facility complements Almac’s specialty capabilities, including biocatalysis, radiolabelling, and peptide and protein synthesis. These services are all part of Almac’s comprehensive drug development services, including API and drug product development and GMP manufacture.

Almac will be exhibiting at the forthcoming Informex trade show, 14 – 17 February at Booth 2001.

Notes to Editors

The Almac Group provides a broad range of services from R&D, biomarker discovery and development, API manufacture, formulation development, clinical trial supply and IXRS^® technology (IVRS/IWRS), to commercial-scale manufacture. Almac provides services to more than 600 companies, including all the world leaders in the pharmaceutical and biotech sectors. The company employs over 3,300 individuals and is headquartered in Craigavon, Northern Ireland. US operations are based in Pennsylvania, North Carolina and California.